Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
200 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Spinal Cord Injury - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Pipeline Review, H2 2017, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape. Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 8, 1, 29 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively. Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Spinal Cord Injury - Overview 8 Spinal Cord Injury - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 16 Products under Development by Universities/Institutes 19 Spinal Cord Injury - Therapeutics Assessment 20 Assessment by Target 20 Assessment by Mechanism of Action 23 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Spinal Cord Injury - Companies Involved in Therapeutics Development 30 AbbVie Inc 30 Acorda Therapeutics Inc 31 Aevi Genomic Medicine Inc 31 Apollo Endosurgery Inc 32 Asterias Biotherapeutics Inc 32 Athersys Inc 33 BioArctic AB 33 BioAxone BioSciences Inc 34 Biogen Inc 34 CSL Ltd 35 CSPC Pharmaceutical Group Limited 35 Genervon Biopharmaceuticals LLC 36 Hemostemix Inc 36 Histocell SL 36 K-Stemcell Co Ltd 37 Kadimastem Ltd 37 Kringle Pharma Inc 38 MandalMed Inc 38 Mapreg SAS 38 Neuralstem Inc 39 Neuronax SAS 39 New World Laboratories Inc 40 Pharmicell Co Ltd 40 PixarBio Corp 41 RDD Pharma Ltd 41 RespireRx Pharmaceuticals Inc 42 SanBio Inc 42 Spectrum Pharmaceuticals Inc 43 Stemedica Cell Technologies Inc 43 TissueGene Inc 44 Tumorend LLC 44 Vertex Pharmaceuticals Inc 45 Vicore Pharma AB 45 Spinal Cord Injury - Drug Profiles 46 ABT-555 - Drug Profile 46 APO-1 - Drug Profile 47 ASTOPC-1 - Drug Profile 48 AX-007 - Drug Profile 58 BA-277 - Drug Profile 59 BA-434 - Drug Profile 60 C-21 - Drug Profile 61 Cell Therapy for Spinal Cord Injury - Drug Profile 64 Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 65 Cellgram-SCI - Drug Profile 66 CHEC-9 - Drug Profile 67 chondroitinase ABC nanosphere - Drug Profile 68 CLR-01 - Drug Profile 69 CM-101 - Drug Profile 71 CX-1739 - Drug Profile 72 CX-717 - Drug Profile 77 Drug for Spinal Cord Injury - Drug Profile 79 Drugs to Inhibit ROCK for Spinal Cord Injury - Drug Profile 80 ES-135 - Drug Profile 81 Fusion Protein to Antagonize EPHA4 for Amyotrophic Lateral Sclerosis, Acute Spinal Cord Injury, Sepsis and Ischemia Reperfusion Injury - Drug Profile 82 Gene Therapy for Spinal Cord Injury and Neurodegenerative Diseases - Drug Profile 83 glyburide - Drug Profile 84 GM-603 - Drug Profile 88 HBN-1 - Drug Profile 89 HC-016 - Drug Profile 90 ICCN-100 - Drug Profile 91 immune globulin (human) - Drug Profile 92 IMS-001 - Drug Profile 94 IMS-002 - Drug Profile 95 JM-4 - Drug Profile 96 KP-100IT - Drug Profile 97 laflunimus - Drug Profile 99 LM-11A31BHS - Drug Profile 100 LPA-181 - Drug Profile 102 Lpathomab - Drug Profile 103 MAP-4343 - Drug Profile 106 Monoclonal Antibody to Inhibit Connexin 43 for Spinal Cord Injury - Drug Profile 107 NCP-01 - Drug Profile 108 Neu-2000 - Drug Profile 109 NeuroRelease SCI - Drug Profile 111 neurovitas - Drug Profile 112 NgR(310)ecto-Fc - Drug Profile 113 NOVO-117 - Drug Profile 115 NSI-566 - Drug Profile 116 NWL-53 - Drug Profile 124 NX-210 - Drug Profile 125 Oligonucleotide for Central Nervous System and Metabolic Disorders - Drug Profile 127 oxymetazoline hydrochloride - Drug Profile 128 Peptide to Inhibit CSPG for Spinal Cord Injury and Neurodegenerative Diseases - Drug Profile 130 PF-05285401 - Drug Profile 131 Proteins to Activate BGLAP for Spinal Cord Injury and Autoimmune Disorders - Drug Profile 143 Q-Cells - Drug Profile 144 R-801 - Drug Profile 146 Recombinant Chondroitinase to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile 148 SB-618 - Drug Profile 150 SB-623 - Drug Profile 151 SC-0806 - Drug Profile 156 Small Molecules for Spinal Cord Injury - Drug Profile 157 Small Molecules to Block Voltage-Gated Potassium Channel for Spinal Cord Injury and Multiple Sclerosis - Drug Profile 158 SPI-1620 - Drug Profile 159 Stem Cell Therapy for Central Nervous System Disorders - Drug Profile 161 Stem Cell Therapy for Neurodegenerative Diseases - Drug Profile 162 Stem Cell Therapy for Spinal Cord Injury - Drug Profile 165 Stem Cell Therapy for Spinal Cord Injury - Drug Profile 166 Stem Cell Therapy for Spinal Cord Injury, Alzheimer's Disease, Progressive Supranuclear Palsy and Cerebral Palsy - Drug Profile 167 Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury - Drug Profile 169 Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile 170 TG-N - Drug Profile 171 UH-0113 - Drug Profile 172 UH-0213 - Drug Profile 173 VX-210 - Drug Profile 174 Xcel-hNu - Drug Profile 177 Xcel-hNuP - Drug Profile 178 Spinal Cord Injury - Dormant Projects 179 Spinal Cord Injury - Discontinued Products 183 Spinal Cord Injury - Product Development Milestones 184 Featured News & Press Releases 184 Appendix 194 Methodology 194 Coverage 194 Secondary Research 194 Primary Research 194 Expert Panel Validation 194 Contact Us 194 Disclaimer 195
List of Tables
Number of Products under Development for Spinal Cord Injury, H2 2017 14 Number of Products under Development by Companies, H2 2017 16 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18 Number of Products under Development by Universities/Institutes, H2 2017 20 Products under Development by Companies, H2 2017 21 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 22 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 23 Products under Development by Universities/Institutes, H2 2017 24 Number of Products by Stage and Target, H2 2017 26 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 27 Number of Products by Stage and Mechanism of Action, H2 2017 29 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 30 Number of Products by Stage and Route of Administration, H2 2017 32 Number of Products by Stage and Molecule Type, H2 2017 34 Spinal Cord Injury - Pipeline by AbbVie Inc, H2 2017 35 Spinal Cord Injury - Pipeline by Acorda Therapeutics Inc, H2 2017 36 Spinal Cord Injury - Pipeline by Aevi Genomic Medicine Inc, H2 2017 36 Spinal Cord Injury - Pipeline by Apollo Endosurgery Inc, H2 2017 37 Spinal Cord Injury - Pipeline by Asterias Biotherapeutics Inc, H2 2017 37 Spinal Cord Injury - Pipeline by Athersys Inc, H2 2017 38 Spinal Cord Injury - Pipeline by BioArctic AB, H2 2017 38 Spinal Cord Injury - Pipeline by BioAxone BioSciences Inc, H2 2017 39 Spinal Cord Injury - Pipeline by Biogen Inc, H2 2017 39 Spinal Cord Injury - Pipeline by CSL Ltd, H2 2017 40 Spinal Cord Injury - Pipeline by CSPC Pharmaceutical Group Limited, H2 2017 40 Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals LLC, H2 2017 41 Spinal Cord Injury - Pipeline by Hemostemix Inc, H2 2017 41 Spinal Cord Injury - Pipeline by Histocell SL, H2 2017 41 Spinal Cord Injury - Pipeline by K-Stemcell Co Ltd, H2 2017 42 Spinal Cord Injury - Pipeline by Kadimastem Ltd, H2 2017 42 Spinal Cord Injury - Pipeline by Kringle Pharma Inc, H2 2017 43 Spinal Cord Injury - Pipeline by MandalMed Inc, H2 2017 43 Spinal Cord Injury - Pipeline by Mapreg SAS, H2 2017 43 Spinal Cord Injury - Pipeline by Neuralstem Inc, H2 2017 44 Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2017 44 Spinal Cord Injury - Pipeline by New World Laboratories Inc, H2 2017 45 Spinal Cord Injury - Pipeline by Pharmicell Co Ltd, H2 2017 45 Spinal Cord Injury - Pipeline by PixarBio Corp, H2 2017 46 Spinal Cord Injury - Pipeline by RDD Pharma Ltd, H2 2017 46 Spinal Cord Injury - Pipeline by RespireRx Pharmaceuticals Inc, H2 2017 47 Spinal Cord Injury - Pipeline by SanBio Inc, H2 2017 47 Spinal Cord Injury - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017 48 Spinal Cord Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2017 48 Spinal Cord Injury - Pipeline by TissueGene Inc, H2 2017 49 Spinal Cord Injury - Pipeline by Tumorend LLC, H2 2017 49 Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Inc, H2 2017 50 Spinal Cord Injury - Pipeline by Vicore Pharma AB, H2 2017 50 Spinal Cord Injury - Dormant Projects, H2 2017 184 Spinal Cord Injury - Dormant Projects, H2 2017 (Contd..1), H2 2017 185 Spinal Cord Injury - Dormant Projects, H2 2017 (Contd..2), H2 2017 186 Spinal Cord Injury - Dormant Projects, H2 2017 (Contd..3), H2 2017 187 Spinal Cord Injury - Discontinued Products, H2 2017 188
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
